FDAAdvisoryCommittee.com
10 articles about FDAAdvisoryCommittee.com
-
FDAAdvisoryCommittee.com Approves Celltrion’s INFLECTRA, the First Cheaper Version of Johnson & Johnson Blockbuster Remicade
4/7/2016
-
Ex-FDAAdvisoryCommittee.com Head Accused of Conspiring to Suppress Information About Harmful Effects of Johnson & Johnson Antibiotic
2/11/2016
-
FDAAdvisoryCommittee.com Grants Orphan Drug Status to Eisai Inc.'s Lenvatinib
2/15/2013
-
FDAAdvisoryCommittee.com Rejects United Therapeutics Corporation Lung Drug
10/25/2012
-
FDAAdvisoryCommittee.com : Salix Pharmaceuticals, Ltd. Supports Proposed Clinical Trial Design to Evaluate Repeat Treatment Cycles of XIFAXAN® for Irritable Bowel Syndrome with Diarrhea
11/17/2011
-
FDAAdvisoryCommittee.com Grants Fluke Biomedical 510(k) Clearance for New ProSim(TM) Vital Signs Simulators
9/9/2011
-
FDAAdvisoryCommittee.com Approves Addition of Sustained Overall Survival Benefit to Label for Takeda's (JOBS) VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
1/5/2010
-
FDAAdvisoryCommittee.com to Webcast via TalkPoint the FDA Review of Bayer Corporation and Johnson & Johnson Anti-Clot Drug Rivaroxaban on March 19th
3/11/2009
-
FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS(TM) (raltegravir), Merck & Co., Inc.'s Investigational Oral Integrase Inhibitor, for Treatment of HIV
9/6/2007
-
Columbia Laboratories, Inc. Comments On FDA Reproductive Drugs Advisory Committee Recommendation On 17-OHPC; PROCHIEVE 8% Currently In Phase III Clinical Trial For Prevention Of Recurrent Preterm Birth
8/30/2006